The approved mixed protamine human insulin injection (30R) is premixed insulin composed of 30% soluble human insulin and 70% protamine human insulin. The compound is a prandial insulin that has been studied to be safe and effective in maintaining Type-2 Diabetes (T2D) patients’ blood glucose and HbA1c in a Phase III trial.

In China, proper management of diabetes is a challenge, especially in rural areas. Increased medical expenses may be attributed to poor insulin adherence, which can result in diabetic complications1. Data collected from an open-label, non-randomized, non-interventional, multi-center clinical observational study in 4,837 T2D participants in China, indicated that 38% of patients use premixed human insulin as part of initial treatment regimens2. According to the Catalog of Medicines Covered by the National Medical Insurance System, pre-mixed human insulins are considered Class A drugs, with a reimbursement ratio of 100%3. The approval of Mixed Protamine Human Insulin Injection (30R) is an important milestone for Gan & Lee in China as we strive to provide additional treatment options for patients with diabetes.

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection approved in China - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and working on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. For more information, please contact us at media@ganlee.com

Reference

1. He, X., et al (2017). Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis. Patient preference and adherence, 11, 237.

2.  Ji, L., et al. (2011). Chinese Journal of Diabetes Mellitus. 19(10): 746-51

3. The Catalog of Medicines Covered by National Medical Insurance System (2020). The State Council, The People’s Republic of China. www.gov.cn